Nuveen’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-675,828
| Closed | -$26M | – | 3267 |
|
|
2023
Q2 | $26M | Sell |
675,828
-70,344
| -9% | -$1.81M | 0.01% | 909 |
|
|
2023
Q1 | $17.3M | Sell |
746,172
-170,593
| -19% | -$4.07M | 0.01% | 1139 |
|
|
2022
Q4 | $18.4M | Sell |
916,765
-44,493
| -5% | -$986K | 0.01% | 1101 |
|
|
2022
Q3 | $18.9M | Buy |
961,258
+336,054
| +54% | +$6.74M | 0.01% | 1049 |
|
|
2022
Q2 | $10.9M | Buy |
625,204
+410,711
| +191% | +$6.45M | ﹤0.01% | 1443 |
|
|
2022
Q1 | $3.51M | Buy |
214,493
+60,157
| +39% | +$818K | ﹤0.01% | 2249 |
|
|
2021
Q4 | $2.52M | Sell |
154,336
-23,819
| -13% | -$339K | ﹤0.01% | 2458 |
|
|
2021
Q3 | $2.27M | Sell |
178,155
-6,231
| -3% | -$82K | ﹤0.01% | 2613 |
|
|
2021
Q2 | $1.5M | Buy |
184,386
+111,751
| +154% | +$1.79M | ﹤0.01% | 2833 |
|
|
2021
Q1 | $1.03M | Sell |
72,635
-2,455
| -3% | -$40K | ﹤0.01% | 2875 |
|
|
2020
Q4 | $1.19M | Buy |
75,090
+5,281
| +8% | +$79.7K | ﹤0.01% | 2743 |
|
|
2020
Q3 | $848K | Sell |
69,809
-1,029
| -1% | -$13.8K | ﹤0.01% | 2752 |
|
|
2020
Q2 | $819K | Sell |
70,838
-13,355
| -16% | -$184K | ﹤0.01% | 2703 |
|
|
2020
Q1 | $1.15M | Buy |
+84,193
| New | +$996K | ﹤0.01% | 2453 |
|
Nuveen's KDNY Position: Q3 2023 in Review
Nuveen sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 675,828 shares — an estimated $26M sold.
Nuveen first reported a position in KDNY in Q1 2020 and held it in 14 quarters. The position peaked at $26M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Nuveen reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Nuveen sold 675,828 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $26M.
- Nuveen first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2020 and held it in 14 quarters.
- Nuveen's Chinook Therapeutics, Inc. Common Stock position peaked at $26M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Nuveen's 13F filing for Q3 2023, filed 14 Nov 2023.